FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

James Raftery

Research Profile

Activities & Behaviors

Geographic Areas

Concepts & Ideas

Procedures

Disorders

Myocardial Infarction

Chemicals & Drugs

Anticoagulants

Co-author Network

Publications

TOP 3
James Raftery; Louise Dent; Lisa Douet; Eleanor Fairbank; Ruairidh Milne; Alison Price; Tom Walley
Registration of noncommercial randomised clinical trials: the feasibility of using trial registries to monitor the number of trials.
Louise Dent; James Raftery
Treatment success in pragmatic randomised controlled trials: a review of trials funded by the UK Health Technology Assessment programme.
Louise Dent; Rod Taylor; Kate Jolly; James Raftery
"Flogging dead horses": evaluating when have clinical trials achieved sufficiency and stability? A case study in cardiac rehabilitation.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of James Raftery (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: James Raftery; Louise Dent; Lisa Douet; Eleanor Fairbank; Ruairidh Milne; Alison Price; Tom Walley
Registration of noncommercial randomised clinical trials: the feasibility of using trial registries to monitor the number of trials.
Trials 2012;13():140.
2011: Louise Dent; James Raftery
Treatment success in pragmatic randomised controlled trials: a review of trials funded by the UK Health Technology Assessment programme.
Trials 2011;12():109.
2011: Louise Dent; Rod Taylor; Kate Jolly; James Raftery
"Flogging dead horses": evaluating when have clinical trials achieved sufficiency and stability? A case study in cardiac rehabilitation.
Trials 2011;12():83.
2011: David Turner; James Raftery; Keith Cooper; Eleanor Fairbank; Stephen Palmer; Sue Ward; Roberta Ara
The CHD challenge: comparing four cost-effectiveness models.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2011;14(1):53-60.
2010: James Raftery
Multiple sclerosis risk sharing scheme: a costly failure.
BMJ (Clinical research ed.) 2010;340():c1672.
2009: James Raftery; L Dent
Should Avastin be used to treat age-related macular degeneration in the NHS?--Yes.
Eye (London, England) 2009;23(6):1247-9.
2009: Lucy Yardley; Sarah Kirby; Fiona Barker; Paul Little; James Raftery; Debbie King; Anna Morris; Mark Mullee
An evaluation of the cost-effectiveness of booklet-based self-management of dizziness in primary care, with and without expert telephone support.
BMC ear, nose, and throat disorders 2009;9():13.
2009: Rob Jones; Bart Sheehan; Patrick Phillips; Ed Juszczak; Jessica Adams; Ashley Baldwin; Clive G Ballard; Sube Banerjee; Bob Barber; Peter Bentham; Richard Brown; Alistair Burns; Tom Dening; David Findlay; Richard Gray; Mary Griffin; Clive Holmes; Alan Hughes; Robin Jacoby; Tony Johnson; Roy Jones; Martin Knapp; James Lindesay; Ian G McKeith; Rupert McShane; Ajay Macharouthu; John T O'Brien; Caroline Onions; Peter Passmore; James Raftery; Craig Ritchie; Rob Howard
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT.
Trials 2009;10():57.
2009: James Raftery
Regulation of drug pricing in australia, England, and new zealand.
Clinical advances in hematology & oncology : H&O 2009;7(1):26-8.
2009: James Raftery; Christine Kerr; Sheila Hawker; John Powell
Paying clinicians to join clinical trials: a review of guidelines and interview study of trialists.
Trials 2009;10():15.
2009: James Raftery
Should NICE's threshold range for cost per QALY be raised? No.
BMJ (Clinical research ed.) 2009;338():b185.
2009: James Raftery
NICE and the challenge of cancer drugs.
BMJ (Clinical research ed.) 2009;338():b67.
2009: James Raftery; Stephen Hanney; Colin Green; Martin Buxton
Assessing the impact of England's National Health Service R&D Health Technology Assessment program using the "payback" approach.
International journal of technology assessment in health care 2009;25(1):1-5.
2009: Kate Jolly; G Y H Lip; Rod S Taylor; James Raftery; Jonathan Mant; Deirdre Lane; Sheila Greenfield; Andrew J Stevens
The Birmingham Rehabilitation Uptake Maximisation study (BRUM): a randomised controlled trial comparing home-based with centre-based cardiac rehabilitation.
Heart (British Cardiac Society) 2009;95(1):36-42.
2008: James Raftery; Jackie Bryant; Jackie Powell; Chris Kerr; Sheila Hawker
Payment to healthcare professionals for patient recruitment to trials: systematic review and qualitative study.
Health technology assessment (Winchester, England) 2008;12(10):1-128, iii.
2008: James Raftery
Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand.
The Medical journal of Australia 2008;188(1):26-8.
2008: Peter Bentham; Richard Gray; E Sellwood; Robert K Hills; P Crome; James Raftery
Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial.
Lancet neurology 2008;7(1):41-9.
2007: Steve Hanney; Martin Buxton; Colin Green; D Coulson; James Raftery
An assessment of the impact of the NHS Health Technology Assessment Programme.
Health technology assessment (Winchester, England) 2007;11(53):iii-iv, ix-xi, 1-180.
2007: Kate Jolly; Rod S Taylor; G Yh Lip; Sheila Greenfield; James Raftery; Jonathan Mant; Deirdre Lane; M Jones; K W Lee; Andrew J Stevens
The Birmingham Rehabilitation Uptake Maximisation Study (BRUM). Home-based compared with hospital-based cardiac rehabilitation in a multi-ethnic population: cost-effectiveness and patient adherence.
Health technology assessment (Winchester, England) 2007;11(35):1-118.
2007: Miren Jones; Kate Jolly; James Raftery; Gregory Y H Lip; Sheila Greenfield
'DNA' may not mean 'did not participate': a qualitative study of reasons for non-adherence at home- and centre-based cardiac rehabilitation.
Family practice 2007;24(4):343-57.
2007: James Raftery; Andrew Clegg; Jeremy Jones; Seng Chuen Tan; Andrew J Lotery
Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness.
The British journal of ophthalmology 2007;91(9):1244-6.
2007: David Fitzmaurice; F D Richard Hobbs; Sue Jowett; Jonathan Mant; Ellen T Murray; Roger L Holder; James Raftery; Stirling Bryan; Michael Davies; Gregory Y H Lip; Teresa F Allan
Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial.
BMJ (Clinical research ed.) 2007;335(7616):383.
2007: D G T Whitehurst; Martyn Lewis; Guiqing L Yao; Stirling Bryan; James Raftery; Ricky Mullis; Elaine M Hay
A brief pain management program compared with physical therapy for low back pain: results from an economic analysis alongside a randomized clinical trial.
Arthritis and rheumatism 2007;57(3):466-73.
2007: Jayne Wilson; Guiqing L Yao; James Raftery; Julia Bohlius; Susan Brunskill; Josie Sandercock; Sue Bayliss; Paul Moss; Simon Stanworth; Chris Hyde
A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.
Health technology assessment (Winchester, England) 2007;11(13):1-202, iii-iv.
2007: James Raftery; Andrew J Lotery
The cheaper drug, bevacizumab, should be referred to NICE.
BMJ (Clinical research ed.) 2007;334(7590):381-2.
2007: Alec H Miners; Guiqing Yao; James Raftery; Rod S Taylor
Economic evaluations of calcineurin inhibitors in renal transplantation: a literature review.
PharmacoEconomics 2007;25(11):935-47.
2006: G Yao; Esther Albon; Yaser Adi; David V Milford; Sue Bayliss; Andrew R Ready; James Raftery; Rod S Taylor
A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children.
Health technology assessment (Winchester, England) 2006;10(49):iii-iv, ix-xi, 1-157.
2006: K Cooper; Sally Brailsford; Ruth Davies; James Raftery
A review of health care models for coronary heart disease interventions.
Health care management science 2006;9(4):311-24.
2006: Sue Jowett; Stirling Bryan; Ellen Murray; Deborah McCahon; James Raftery; F D Richard Hobbs; David Fitzmaurice
Patient self-management of anticoagulation therapy: a trial-based cost-effectiveness analysis.
British journal of haematology 2006;134(6):632-9.
2006: James Raftery
Review of NICE's recommendations, 1999-2005.
BMJ (Clinical research ed.) 2006;332(7552):1266-8.
2006: D Chase; Paul Roderick; K Cooper; R Davies; Tom Quinn; James Raftery
Using simulation to estimate the cost effectiveness of improving ambulance and thrombolysis response times after myocardial infarction.
Emergency medicine journal : EMJ 2006;23(1):67-72.
2005: Janine Dretzke; Emma J Frew; Clare Davenport; J Barlow; Sarah Stewart-Brown; Josie Sandercock; Sue Bayliss; James Raftery; Chris Hyde; Rod S Taylor
The effectiveness and cost-effectiveness of parent training/education programmes for the treatment of conduct disorder, including oppositional defiant disorder, in children.
Health technology assessment (Winchester, England) 2005;9(50):iii, ix-x, 1-233.
2005: David Fitzmaurice; Ellen T Murray; Deborah McCahon; Roger L Holder; James Raftery; Shakir Hussain; HS Sandhar; F D Richard Hobbs
Self management of oral anticoagulation: randomised trial.
BMJ (Clinical research ed.) 2005;331(7524):1057.
2005: F D Richard Hobbs; David Fitzmaurice; Jonathan Mant; Ellen Murray; Sue Jowett; Stirling Bryan; James Raftery; M Davies; G Lip
A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study.
Health technology assessment (Winchester, England) 2005;9(40):iii-iv, ix-x, 1-74.
2005: Jayne Wilson; Martin Connock; Fujian Song; G Yao; Anne Fry-Smith; James Raftery; DR Peake
Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.
Health technology assessment (Winchester, England) 2005;9(25):1-142.
2005: R Woodroffe; Guiqing L Yao; Catherine Meads; Sue Bayliss; Andrew R Ready; James Raftery; Rod S Taylor
Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
Health technology assessment (Winchester, England) 2005;9(21):1-179, iii-iv.
2005: James Raftery; Paul Roderick; Andrew J Stevens
Potential use of routine databases in health technology assessment.
Health technology assessment (Winchester, England) 2005;9(20):1-92, iii-iv.
2005: James Raftery; Guiqing L Yao; Peter Murchie; Neil C Campbell; Lewis D Ritchie
Cost effectiveness of nurse led secondary prevention clinics for coronary heart disease in primary care: follow up of a randomised controlled trial.
BMJ (Clinical research ed.) 2005;330(7493):707.
2005: Mohammed A Mohammed; Jonathan Mant; Louise Bentham; James Raftery
Comparing processes of stroke care in high- and low-mortality hospitals in the West Midlands, UK.
International journal for quality in health care : journal of the International Society for Quality in Health Care / ISQua 2005;17(1):31-6.
2005: Sue Simpson; Claire Packer; Andrew J Stevens; James Raftery
Predicting the impact of new health technologies on average length of stay: development of a prediction framework.
International journal of technology assessment in health care 2005;21(4):487-91.
2005: Andrew J Stevens; James Raftery; Paul Roderick
Can health technologies be assessed using routine data?
International journal of technology assessment in health care 2005;21(1):96-103.
2004: Dawn Swancutt; Richard F D Hobbs; David Fitzmaurice; Jonathan Mant; Ellen Murray; Sue Jowett; James Raftery; Stirling Bryan; Michael Davies; Gregory Lip
A randomised controlled trial and cost effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in the over 65s: (SAFE) [ISRCTN19633732].
BMC cardiovascular disorders 2004;4():12.
2004: C Courtney; D Farrell; Richard Gray; Robert K Hills; L Lynch; E Sellwood; S Edwards; W Hardyman; James Raftery; P Crome; Corinne Lendon; H Shaw; Peter Bentham
Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.
Lancet 2004;363(9427):2105-15.
2004: Mohammed A Mohammed; James Raftery; Martin LeatherBarrow; Mike Harley; Tom Marshall
Counting in-hospital deaths in England: a comparison of hospital computer systems and mortuary registers.
Journal of health services research & policy 2004;9(2):100-3.
2004: Claire Packer; Andrew J Stevens; Alison Cook; James Raftery
Diffusion of thrombolysis for acute myocardial infarction from 1981 to 2000 in England: trend analysis and comparison with need.
International journal of technology assessment in health care 2004;20(4):531-6.
2004: Janine Dretzke; W D Toff; G Y H Lip; James Raftery; Anne Fry-Smith; Rod S Taylor
Dual chamber versus single chamber ventricular pacemakers for sick sinus syndrome and atrioventricular block.
Cochrane database of systematic reviews (Online) 2004;(2):CD003710.
2003: Naomi E Chayen; Michele Cianci; J Günter Grossmann; Jarjis Habash; John R Helliwell; Gwen A Nneji; James Raftery; Pierre J Rizkallah; Peter F Zagalsky
Unravelling the structural chemistry of the colouration mechanism in lobster shell.
Acta crystallographica. Section D, Biological crystallography 2003;59(Pt 12):2072-82.
2003: Deborah McCahon; David Fitzmaurice; Ellen T Murray; Christopher J Fuller; Richard F D Hobbs; Teresa F Allan; James Raftery
SMART: self-management of anticoagulation, a randomised trial [ISRCTN19313375].
BMC family practice 2003;4():11.
2003: Kate Jolly; Gregory Y H Lip; Josie Sandercock; Sheila M Greenfield; James Raftery; Jonathan Mant; Rod S Taylor; Deirdre Lane; Kaeng Wai Lee; Andrew J Stevens
Home-based versus hospital-based cardiac rehabilitation after myocardial infarction or revascularisation: design and rationale of the Birmingham Rehabilitation Uptake Maximisation Study (BRUM): a randomised controlled trial [ISRCTN72884263].
BMC cardiovascular disorders 2003;3():10.
2003: Jonathan Mant; Suzanne H Richards; F D Richard Hobbs; David Fitzmaurice; Gregory Y H Lip; Ellen Murray; Miriam Banting; Kate Fletcher; Joy Rahman; Teresa F Allan; James Raftery; Stirling Bryan
Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [ISRCTN89345269].
BMC cardiovascular disorders 2003;3():9.
2003: Paul Roderick; Ruth Davies; James Raftery; David Crabbe; R Pearce; Praful Patel; P Bhandari
Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation.
Journal of medical screening 2003;10(3):148-56.
2003: W Clark; James Raftery; Fujian Song; Pelham M Barton; Carole Cummins; Anne Fry-Smith; Amanda Burls
Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease.
Health technology assessment (Winchester, England) 2003;7(3):1-67.
2003: Paul Roderick; Ruth Davies; James Raftery; David Crabbe; R Pearce; P Bhandari; Praful Patel
The cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model.
Health technology assessment (Winchester, England) 2003;7(6):1-86.
2002: Keith Cooper; Ruth Davies; Paul Roderick; Debbie Chase; James Raftery
The development of a simulation model of the treatment of coronary heart disease.
Health care management science 2002;5(4):259-67.
2002: Ruth Davies; David Crabbe; Paul Roderick; Jonathan R Goddard; James Raftery; Praful Patel
A simulation to evaluate screening for Helicobacter pylori infection in the prevention of peptic ulcers and gastric cancers.
Health care management science 2002;5(4):249-58.
2002: Fujian Song; James Raftery; Paul Aveyard; Chris Hyde; Pelham M Barton; Nerys F Woolacott
Cost-effectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis.
Medical decision making : an international journal of the Society for Medical Decision Making 2002;22(5 Suppl):S26-37.
2002: James Raftery
NHS activity. Running out of juice.
The Health service journal 2002;112(5802):22-3.
2001: James Raftery
NICE: faster access to modern treatments? Analysis of guidance on health technologies.
BMJ (Clinical research ed.) 2001;323(7324):1300-3.
2001: Anthony Robert Kendrick; L Stevens; A Bryant; J Goddard; Andrew J Stevens; James Raftery; Christopher Thompson
Hampshire depression project: changes in the process of care and cost consequences.
The British journal of general practice : the journal of the Royal College of General Practitioners 2001;51(472):911-3.
2001: C Salas; James Raftery
Econometric issues in testing the age neutrality of health care expenditure.
Health economics 2001;10(7):669-71.
2001: Paul Roderick; J Low; R Day; T Peasgood; MA Mullee; JC Turnbull; T Villar; James Raftery
Stroke rehabilitation after hospital discharge: a randomized trial comparing domiciliary and day-hospital care.
Age and ageing 2001;30(4):303-10.
2000: D Parry; David Fitzmaurice; James Raftery
Anticoagulation management in primary care: a trial-based economic evaluation.
British journal of haematology 2000;111(2):530-3.
2000: Naomi E Chayen; Michele Cianci; Andrzej Olczak; James Raftery; Pierre J Rizkallah; Peter F Zagalsky; John R Helliwell
Apocrustacyanin A1 from the lobster carotenoprotein alpha-crustacyanin: crystallization and initial X-ray analysis involving softer X-rays.
Acta crystallographica. Section D, Biological crystallography 2000;56(Pt 8):1064-6.
2000: James Raftery
Costing in economic evaluation.
BMJ (Clinical research ed.) 2000;320(7249):1597.
2000: Brendan Delaney; Paul Moayyedi; J Deeks; Michael Innes; S Soo; Pelham M Barton; Sue Wilson; R A L Oakes; A Harris; James Raftery; Richard F D Hobbs; David Forman
The management of dyspepsia: a systematic review.
Health technology assessment (Winchester, England) 2000;4(39):iii-v, 1-189.
2000: A Joseph Kalb; Jarjis Habash; N S Hunter; H J Price; James Raftery; John R Helliwell
Manganese(II) in concanavalin A and other lectin proteins.
Metal ions in biological systems 2000;37():279-304.
1999: James Raftery
Methodological limitations of cost-effectiveness analysis in health care: implications for decision making and service provision.
Journal of evaluation in clinical practice 1999;5(4):361-6.
1999: Naomi E Chayen; Titus Boggon; James Raftery; John R Helliwell; Peter F Zagalsky
Purification, crystallization and initial X-ray analysis of the C1 subunit of the astaxanthin protein, V600, of the chondrophore Velella velella.
Acta crystallographica. Section D, Biological crystallography 1999;55(Pt 1):266-8.
1998: James Raftery; Andrew J Stevens
Day case surgery trends in England: the influences of target setting and of general practitioner fundholding.
Journal of health services research & policy 1998;3(3):149-52.
1998: James Raftery
Economic evaluation: an introduction.
BMJ (Clinical research ed.) 1998;316(7136):1013-4.
1997: C Bowie; S Beck; Gwyn Bevan; James Raftery; F Silverton; A Stevens
Estimating the burden of disease in an English region.
Journal of public health medicine 1997;19(1):87-92.
1996: Naomi E Chayen; Titus Boggon; A Cassetta; A Deacon; T Gleichmann; J Habash; S J Harrop; John R Helliwell; Y P Nieh; M R Peterson; James Raftery; Edward H Snell; A Hädener; A C Niemann; D P Siddons; vivian stojanoff; A W Thompson; T Ursby; M Wulff
Trends and challenges in experimental macromolecular crystallography.
Quarterly reviews of biophysics 1996;29(3):227-78.
1996: James Raftery; R Robinson; J A Mulligan; S Forrest
Contracting in the NHS quasi-market.
Health economics 1996;5(4):353-62.
1996: James Raftery; Julia Addington-Hall; L D MacDonald; H Ross Anderson; J M Bland; J Chamberlain; P Freeling
A randomized controlled trial of the cost-effectiveness of a district co-ordinating service for terminally ill cancer patients.
Palliative medicine 1996;10(2):151-61.